RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to tame Tough-to-Treat lymphoma
Disease control OngoingThis study is for adults whose aggressive lymphoma has returned or not responded to prior treatment. It compares a new two-drug combination (loncastuximab tesirine plus rituximab) against standard immunochemotherapy. The main goal is to see which treatment better delays the cance…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: ADC Therapeutics S.A. • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
Major trial tests new drug combo for Tough-to-Treat blood cancer
Disease control OngoingThis large, international Phase 3 study is testing whether adding a newer drug called polatuzumab vedotin to a standard chemotherapy combination (R-ICE) works better for controlling aggressive lymphoma that has come back or didn't respond to first treatment. About 306 adults with…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE3 • Sponsor: GWT-TUD GmbH • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC
-
Scientists test new drug duo in fight against Tough-to-Treat blood cancer
Disease control OngoingThis study is testing whether combining two existing cancer drugs, copanlisib and venetoclax, can help control an aggressive type of lymphoma called DLBCL that has returned or stopped responding to other treatments. The first part of the study aims to find a safe dose, and the se…
Matched conditions: RELAPSED DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC